Coxsackie virus b compositions and methods of use thereof

By inducing an immune response in individuals using CVB composition vaccine, the problem of difficult to effectively prevent the disease caused by Coxsackie virus B in the prior art is solved, and efficient immune protection and safe vaccination effects are achieved.

CN118922205APending Publication Date: 2024-11-08VAC TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280084613.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-21
Filing Date
2022-10-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively induce an immune response against the Coxsackie virus B composition (CVB), especially in preventing its associated diseases.

Method used

Provided compositions comprising inactivated CVB viral particles, virus-like particles or CVB polypeptides induce an immune response to CVB in an individual by vaccination, including CVB compositions of different serotypes, such as CVB1 to CVB5, using inactivated or Virus-like particles form, combined with adjuvant to enhance immune response.

Benefits of technology

It significantly improves the neutralizing antibody titer of CVB to CVB, provides long-term immune protection, reduces the risk of acute CVB infection and related diseases, and does not occur major adverse events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922205A_ABST
    Figure CN118922205A_ABST
Patent Text Reader

Abstract

The present disclosure provides Coxsackie virus B (CVB) compositions and methods of using such compositions to induce an immune response in an individual against CVB.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 271,546 filed on October 25, 2021; U.S. Provisional Patent Application No. 63 / 273,723 filed on October 29, 2021, and U.S. Provisional Patent Application No. 63 / 321,911 filed on March 21, 2022, which are incorporated herein by reference in their entireties. Incorporation by Reference of Electronically Submitted Material A sequence listing is provided herewith as a sequence listing XML "PRVN-V003WO_SEQ_LIST", created on October 21, 2022, and 5KB in size. The contents of the sequence listing XML are incorporated herein by reference in their entirety. Background Art

[0002] Coxsackievirus group B (CVB) is a member of the genus Enterovirus in the family Picornaviridae. There are six recognized serotypes of CVB (1-6): CVB1, CVB2, CVB3, CVB4, CVB5, and CVB6. CVB can cause a variety of diseases, including gastrointestinal disease, myocarditis, pneumonia, aseptic meningitis, encephalitis, and hepatitis. Summary of the invention

[0003] The present disclosure provides coxsackievirus B (CVB) compositions and methods of using such compositions to induce an immune response against CVB in an individual. BRIEF DESCRIPTION OF THE DRAWINGS

[0004] Figure 1 The amino acid sequence of the polyprotein encoded by CVB4 is provided (SEQ ID NO: 1).

[0005] FIG. 2 depicts virus neutralization titers (VNT) against CVB1 to CVB5 in sera of one month vaccinated human subjects after the last dose.

[0006] Figure 3 The peak VNT for each CVB serotype (CVB1-CVB5) is depicted.

[0007] Figure 4-Figure 13 VNT against CVB1 in sera of vaccinated human subjects is depicted ( Figure 4 and Figure 5 ), VNT for CVB2( Figure 6 and Figure 7 ), VNT for CVB3( Figure 8 and Fig. 9 ), VNT for CVB4( Fig.10 and Fig.11), and VNT targeting CBV5 ( Fig.12 and Fig.13 The subject was seropositive for VNT against the indicated CVB serotype prior to vaccination ( Figure 4 , Figure 6 , Figure 8 , Fig.10 and Fig.12 ) or seronegative before vaccination ( Figure 5 , Figure 7 , Fig. 9 , Fig.11 and Fig.13 ).

[0008] Fig.14 Depicted are CVB neutralizing antibody levels in baseline seronegative subjects following vaccination with the CVB composition.

[0009] Fig.15 Depicted are enterovirus-specific absolute IgG levels in the serum of subjects following vaccination with a CVB composition. Data include serum levels during the vaccination period and up to 6 months after the last dose. Data are expressed in enzyme immunoassay units (EIU).

[0010] Fig.16 Depicted are enterovirus-specific IgG levels in the serum of subjects after vaccination with the CVB composition, expressed as the fold increase in enterovirus-specific IgG levels for each individual relative to the baseline measured level.

[0011] Fig.17 Depicted are CVB neutralizing antibody titers for all subjects (baseline seropositive and baseline seronegative) in the sera of subjects after vaccination with the CVB composition. The data include titers during the vaccination period and up to 6 months after the last dose. Titers are expressed on a logarithmic (log2) scale.

[0012] Fig.18 Depicted are VNT in the serum of baseline seronegative individuals following vaccination with the CVB composition. definition

[0013] The terms "subject" and "patient" are used interchangeably herein to refer to an individual (eg, a human) being treated using the methods of the present disclosure.

[0014] As used herein, "Treating" and "treatment" refer to treating a disease or condition of interest in a mammal (e.g., a human) suffering from the disease or condition of interest, and include, for example: (i) inhibiting or reducing the severity of the disease or condition or one or more symptoms thereof, for example, preventing or slowing the development or progression of the disease or condition, and / or ameliorating one or more symptoms; (ii) relieving the disease or condition, i.e., causing regression of the disease or condition or one or more symptoms thereof; and / or (iii) stabilizing the disease or condition.

[0015] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein and refer to a polymeric form of amino acids of any length, which may include genetically encoded and non-genetically encoded amino acids, chemically or biochemically modified or derivatized amino acids; and polypeptides with modified peptide backbones. The terms include: fusion proteins, including but not limited to fusion proteins with heterologous amino acid sequences, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues; immunolabeled proteins; and the like.

[0016] The terms "polynucleotide" and "nucleic acid" used interchangeably herein refer to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. Thus, the term includes, but is not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA; genomic DNA; cDNA; DNA-RNA hybrids; or polymers including purine and pyrimidine bases or other natural, chemically modified or biochemically modified nucleotide bases, non-natural or derived nucleotide bases.

[0017] "Neutralizing antibody" or "virus neutralizing antibody" (VNT) means an antibody that is purified from or present in serum and that recognizes a specific antigen (e.g., a polypeptide encoded by CVB) and inhibits the infectivity of CVB and one or more effects of CVB in a host (e.g., a human).

[0018] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described, as such embodiments may of course vary. It should also be understood that the terminology used herein is only for the purpose of describing specific embodiments and is not intended to be limiting, as the scope of the present invention will only be limited by the appended claims.

[0019] Where a range of values ​​is provided, it is understood that unless the context clearly specifies otherwise, each intermediate value (to one tenth of the unit of the lower limit) between the upper and lower limits of the range and any other stated or intermediate values ​​within the stated range are included within the present invention. The upper and lower limits of these smaller ranges may be independently included within the smaller ranges and are also encompassed within the present invention, subject to any explicit exclusion of the limits within the stated range. Where the stated range includes one or two limits, the range excluding any one or both of those included limits is also included within the present invention.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to the methods and materials described herein may also be used in the practice or detection of the present invention, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials associated with the cited publications.

[0021] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "Coxsackievirus B (CVB)" includes a plurality of such CVBs, and reference to "inactivated viral particles (IVP)" includes reference to one or more IVPs and equivalents thereof known to those skilled in the art, and so forth. It should also be noted that the claims may be drafted to exclude any optional elements. As such, this statement is intended to serve as antecedent basis for use of exclusive terminology such as "solely," "only," and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

[0022] It should be understood that, for the sake of clarity, certain features of the present invention described in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, for the sake of brevity, various features of the present invention described in the context of a single embodiment may also be provided individually or in any suitable sub-combination. All combinations of embodiments belonging to the present invention are specifically encompassed by the present invention and disclosed herein, just as each and every combination is individually and clearly disclosed. In addition, all sub-combinations of various embodiments and elements thereof are also specifically encompassed by the present invention and disclosed herein, just as each and every such sub-combination is individually and clearly disclosed herein.

[0023] The publications discussed herein are provided only for disclosures prior to the filing date of the present application. Nothing herein should be construed as an admission that the present invention is not entitled to predate such publication by virtue of prior invention. In addition, the publication dates provided may differ from the actual publication dates, which may require independent confirmation. DETAILED DESCRIPTION

[0024] The present disclosure provides coxsackievirus B (CVB) compositions and methods of using such compositions to induce an immune response against CVB in an individual. Composition

[0025] The present disclosure provides CVB compositions, wherein such compositions are also referred to herein as "immunogenic compositions". The CVB compositions of the present disclosure can induce an immune response against one or more CVB serotypes in an individual. The CVB compositions of the present disclosure can include intact CVB or portions of CVB. Thus, the term "CVB composition" includes: a) inactivated viral particles (IVPs); b) CVB virus-like particles (VLPs); c) CVB subunits (e.g., one or more CVB polypeptides); and d) one or more nucleic acids comprising a nucleotide sequence encoding one or more CVB polypeptides. CVB-encoded polypeptides include VP1, VP2, VP3, VP4, 2A, 2B, 2C, 3A, 3B, 3C, and 3D. A "CVB composition" may include one or more CVB-encoded polypeptides, or a nucleic acid containing a nucleotide sequence encoding one or more CVB-encoded polypeptides. Unless otherwise expressly indicated, a composition comprising "CVB" refers to a composition comprising CVB IVPs, CVB VLPs, one or more CVB polypeptides, or one or more nucleic acids containing a nucleotide sequence encoding one or more CVB polypeptides.

[0026] Coxsackie B virus (CVB; also referred to herein and in the literature as "Coxsackie B virus" or "CBV") is a group of 6 serotypes (CVB1-CVB6) of Coxsackievirus. In some cases, the compositions of the present disclosure include all 6 serotypes of CVB (in the form of CVB IVPs, CVB VLPs, CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding one or more CVB polypeptides); that is, in some cases, the desired compositions of the present disclosure include CVB1, CVB2, CVB3, CVB4, CVB5, and CVB6. In some cases, the desired compositions of the present disclosure include only 5 serotypes. For example, in some cases, the compositions of the present disclosure include CVB1, CVB2, CVB3, CVB4, and CVB5, but not CVB6. In some cases, the compositions of the present disclosure include only a single CVB serotype. For example, in some cases, the compositions of the present disclosure include only CVB1. As another example, in some cases, the compositions of the present disclosure include only CVB2. As another example, in some cases, the compositions of the present disclosure include only CVB3. As another example, in some cases, the compositions of the present disclosure include only CVB4. As another example, in some cases, the compositions of the present disclosure include only CVB5. In some cases, the compositions of the present disclosure include only 2 different serotypes of CVB (e.g., CVB1 and CVB2; CVB1 and CVB3; CVB1 and CVB4; CVB1 and CVB5; CVB2 and CVB3; CVB2 and CVB4; CVB2 and CVB5; CVB3 and CVB4, CVB3 and CVB5; or CVB4 and CVB5), and do not include any other serotypes of CVB. In some cases, the compositions of the present disclosure include only 3 different serotypes of CVB (e.g., CVB1, CVB2, and CVB3; CVB1, CVB2, and CVB4; CVB1, CVB2, and CVB5; CVB1, CVB3, and CVB4; CVB1, CVB3, and CVB5; CVB2, CVB3, and CVB4; CVB2, CVB3, and CVB5; CVB3, CVB4, and CVB5), and do not include any other serotypes of CVB. In some cases, the compositions of the present disclosure include only 4 different serotypes of CVB (e.g., the composition may exclude: CVB3 and CVB6; CVB4 and CVB6; CVB5 and CVB6; any other combination of 2 CVB serotypes).

[0027] In some cases, the compositions of the present disclosure do not include any enterovirus other than CVB. For example, in some cases, the compositions of the present disclosure do not include any whole virus, inactivated virus, viral protein (e.g., viral subunit) or nucleic acid encoding a viral protein of an enterovirus other than CVB.

[0028] In some cases, the compositions of the present disclosure comprise one or more serotypes of CVB, wherein the CVB is in an "inactivated" form, meaning that the infectivity of the virus has been reduced or eliminated. The term as used herein also includes replication-defective viruses. A replication-defective virus is a virus that is defective for constitutive proteins. Such a virus can enter cells, deliver a portion of the genome, translate the encoded proteins and replicate the genome, but cannot encapsulate new particles. Therefore, it cannot spread to adjacent cells or tissues.

[0029] Inactivated CVB (CVB IVP) can be produced by propagating the virus in cell culture and purifying the virus from infected cells and culture medium by high-speed centrifugation with a density gradient formed by sucrose or other high-density media. Alternatively, the virus can be purified by chromatography. The infectivity of the purified virus can be destroyed by inactivating the virus by chemical treatment (e.g., formalin inactivation, such as used in the production of inactivated poliovirus vaccines), irradiation or heat treatment. Replication-deficient viruses can be prepared by physical or genetic inactivation, such as by deleting structural genes in the viral genome and generating a complementing cell line that constitutively expresses the protein encoded by the deleted gene, so as to replicate the defective virus. In some cases, the composition of the present disclosure includes formalin-inactivated CVB IVP.

[0030] In some cases, the compositions of the present disclosure comprise two to five serotypes of CVB, wherein the CVB is in the form of an IVP, a CVB VLP, one or more CVB polypeptides, or one or more nucleic acids comprising one or more nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition comprises two or more of the following:

[0031] a) CVB1, the amount of which is from 2.0x10 7 IVP to 2.5x10 8 IVPs;

[0032] b) CVB2, the amount of which is from 1.0x10 7 IVP to 1.5x10 8 IVPs;

[0033] c) CVB3, the amount of which is from 1.0x10 8 IVP to 1.5x10 9IVPs;

[0034] d) CVB4, the amount of which is from 2.0x10 7 IVP to 2.5x10 8 IVPs; and

[0035] e) CVB5, the amount of which is from 4.0x10 7 IVP to 4.0x10 8 IVPs,

[0036] Or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides, wherein the amount of CVB is present in a volume of from about 75 μL to about 600 μL (e.g., from about 75 μL to about 100 μL, from about 100 μL to about 150 μL, from about 150 μL to about 200 μL, from about 200 μL to about 250 μL, from about 250 μL to about 300 μL, from about 300 μL to about 350 μL, from about 350 μL to about 400 μL, from about 400 μL to about 450 μL, from about 450 μL to about 500 μL, from about 500 μL to about 550 μL, or from about 550 μL to about 600 μL). In some cases, the composition comprises the amount of CVB in a volume of 100 μL. In some cases, the composition comprises the amount of CVB in a volume of 500 μL. In some cases, the composition does not include CBV6.

[0037] In some cases, the compositions of the present disclosure comprise two to five serotypes of CVB, wherein the CVB is in the form of an IVP, a CVB VLP, one or more CVB polypeptides, or one or more nucleic acids comprising one or more nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition comprises two or more of the following:

[0038] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0039] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0040] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0041] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x107 IVPs; and

[0042] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0043] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides. The amount of CVB can have a volume of from about 75 μL to about 150 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL, or from about 140 μL to about 150 μL. In some cases, the composition comprises the amount of CVB in a volume of 100 μL. In some cases, the composition does not include CBV6.

[0044] In some cases, the compositions of the present disclosure comprise two to five serotypes of CVB, wherein the CVB is in the form of an IVP, a CVB VLP, one or more CVB polypeptides, or one or more nucleic acids comprising one or more nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition comprises two or more of the following:

[0045] a) CVB1, the amount of which ranges from 1.0x10 8 IVP to 2.5x10 8 IVPs;

[0046] b) CVB2, the amount of which is from 5.0x10 7 IVP to 1.5x10 8 IVPs;

[0047] c) CVB3, the amount of which is from 5.0x10 8 IVP to 1.5x10 9 IVPs;

[0048] d) CVB4, the amount of which is from 1.0x10 8 IVP to 2.5x10 8 IVPs; and

[0049] e) CVB5, the amount of which is from 2.0x10 8 IVP to 4.0x10 8 IVPs,

[0050] Or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides. The amount of CVB can have a volume of from about 400 μL to about 450 μL, from about 450 μL to about 500 μL, from about 500 μL to about 550 μL, or from about 550 μL to about 600 μL. In some cases, the composition includes the amount of CVB in a volume of 500 μL. In some cases, the composition does not include CBV6.

[0051] In some cases, the compositions of the present disclosure include:

[0052] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0053] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0054] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0055] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0056] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0057] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides. The amount of CVB can have a volume of from about 75 μL to about 150 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL, or from about 140 μL to about 150 μL. In some cases, the composition comprises the amount of CVB in a volume of 100 μL. In some cases, the composition does not include CBV6.

[0058] In some cases, the compositions of the present disclosure include:

[0059] a) CVB1, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs;

[0060] b) CVB2, the amount of which is from 1.0x10 7 IVP to 2.0x10 7 IVPs;

[0061] c) CVB3, the amount of which is from 1.0x10 8 IVP to 2.0x10 8 IVPs;

[0062] d) CVB4, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs; and

[0063] e) CVB5, the amount of which is from 6.0x10 7 IVP to 6.0x10 7 IVPs,

[0064] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides. The amount of CVB can have a volume of from about 75 μL to about 150 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL, or from about 140 μL to about 150 μL. In some cases, the composition comprises the amount of CVB in a volume of 100 μL. In some cases, the composition does not include CBV6.

[0065] In some cases, the compositions of the present disclosure include:

[0066] a) CVB1: 3.3x10 7 IVPs;

[0067] b) CVB2: 1.1x10 7 IVPs;

[0068] c)CVB3 1.5x10 8 IVPs;

[0069] d) CVB4: 3.2x10 7 IVPs; and

[0070] e) CVB5: 6.3x10 7 IVPs,

[0071] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides. The amount of CVB can have a volume of from about 75 μL to about 150 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL, or from about 140 μL to about 150 μL. In some cases, the composition comprises the amount of CVB in a volume of 100 μL. In some cases, the composition does not include CBV6.

[0072] In some cases, the compositions of the present disclosure include:

[0073] a) CVB1: 1.6x10 8 IVPs;

[0074] b) CVB2: 5.5x10 7 IVPs;

[0075] c) CVB3: 4.5x10 9 IVPs;

[0076] d) CVB4: 1.6x10 8 IVPs; and

[0077] e) CVB5: 4.8x10 8 In some cases, the composition comprises a volume of about 500 μL of CVB. In some cases, the composition comprises a volume of about 500 μL of CVB. In some cases, the composition does not include CBV6.

[0078] In some cases, the compositions of the present disclosure include:

[0079] a) CVB1: 1.6x10 8 IVPs;

[0080] b) CVB2: 5.5x10 7 IVPs;

[0081] c) CVB3: 7.5x10 8 IVPs;

[0082] d) CVB4: 1.6x10 8 IVPs; and

[0083] e) CVB5: 3.1x10 8 In some cases, the composition comprises a volume of about 500 μL of CVB. In some cases, the composition comprises a volume of about 500 μL of CVB. In some cases, the composition does not include CBV6.

[0084] In some cases, the compositions of the present disclosure include:

[0085] a) CVB1, the amount of which is from 2.0x10 7 IVP to 2.5x10 8 IVPs;

[0086] b) CVB2, the amount of which is from 1.0x10 7 IVP to 1.5x10 8 IVPs;

[0087] c) CVB3, the amount of which is from 1.0x10 8 IVP to 1.5x10 9 IVPs;

[0088] d) CVB4, the amount of which is from 2.0x10 7 IVP to 2.5x10 8 IVPs; and

[0089] e) CVB5, the amount of which is from 4.0x10 7 IVP to 4.0x10 8 IVPs,

[0090] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides. The amount of CVB can have a volume of from about 75 μL to about 600 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL). From about 10 μL to about 20 μL, from about 140 μL to about 150 μL, from about 150 μL to about 200 μL, from about 200 μL to about 250 μL, from about 250 μL to about 300 μL, from about 300 μL to about 350 μL, from about 350 μL to about 400 μL, from about 400 μL to about 450 μL, from about 450 μL to about 500 μL, from about 500 μL to about 550 μL, or from about 550 μL to about 600 μL). In some cases, the composition does not include CBV6.

[0091] In some cases, the compositions of the present disclosure include two or more of the following:

[0092] a) CVB1 in an amount from about 1 μg protein to about 50 μg protein (e.g., from about 1 μg to 2 μg, from 2 μg to 3 μg, from 3 μg to 5 μg, from 5 μg to 10 μg, from 10 μg to 15 μg, from 15 μg to 20 μg, from 20 μg to 25 μg, from 25 μg to 30 μg, from 30 μg to 35 μg, from 35 μg to 40 μg, from 40 μg to 45 μg, or from 45 μg to 50 μg);

[0093] b) CVB2 in an amount from about 1 μg protein to about 50 μg protein (e.g., from about 1 μg to 2 μg, from 2 μg to 3 μg, from 3 μg to 5 μg, from 5 μg to 10 μg, from 10 μg to 15 μg, from 15 μg to 20 μg, from 20 μg to 25 μg, from 25 μg to 30 μg, from 30 μg to 35 μg, from 35 μg to 40 μg, from 40 μg to 45 μg, or from 45 μg to 50 μg);

[0094] c) CVB3 in an amount from about 1 μg protein to about 50 μg protein (e.g., from about 1 μg to 2 μg, from 2 μg to 3 μg, from 3 μg to 5 μg, from 5 μg to 10 μg, from 10 μg to 15 μg, from 15 μg to 20 μg, from 20 μg to 25 μg, from 25 μg to 30 μg, from 30 μg to 35 μg, from 35 μg to 40 μg, from 40 μg to 45 μg, or from 45 μg to 50 μg);

[0095] d) CVB4 in an amount from about 1 μg protein to about 50 μg protein (e.g., from about 1 μg to 2 μg, from 2 μg to 3 μg, from 3 μg to 5 μg, from 5 μg to 10 μg, from 10 μg to 15 μg, from 15 μg to 20 μg, from 20 μg to 25 μg, from 25 μg to 30 μg, from 30 μg to 35 μg, from 35 μg to 40 μg, from 40 μg to 45 μg, or from 45 μg to 50 μg); and

[0096] e) CVB5 in an amount from about 1 μg protein to about 50 μg protein (e.g., from about 1 μg to 2 μg, from 2 μg to 3 μg, from 3 μg to 5 μg, from 5 μg to 10 μg, from 10 μg to 15 μg, from 15 μg to 20 μg, from 20 μg to 25 μg, from 25 μg to 30 μg, from 30 μg to 35 μg, from 35 μg to 40 μg, from 40 μg to 45 μg, or from 45 μg to 50 μg), with a total amount of protein from about 5 μg to about 250 μg. The amount of protein can have a volume of from about 75 μL to about 600 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL, from about 150 μL to about 160 μL, from about 170 μL to about 180 μL, from about 190 μL to about 200 μL, from about 210 μL to about 220 μL, from about 230 μL to about 240 μL, from about 250 μL to about 260 μL, from about 270 μL to about 280 μL From about 10 μL to about 20 μL, from about 140 μL to about 150 μL, from about 150 μL to about 200 μL, from about 200 μL to about 250 μL, from about 250 μL to about 300 μL, from about 300 μL to about 350 μL, from about 350 μL to about 400 μL, from about 400 μL to about 450 μL, from about 450 μL to about 500 μL, from about 500 μL to about 550 μL, or from about 550 μL to about 600 μL). In some cases, the composition does not include CBV6.

[0097] In some cases, the compositions of the present disclosure include:

[0098] a) CVB1 in an amount from about 2 μg protein to about 4 μg protein;

[0099] b) CVB2 in an amount from about 1 μg protein to about 2.5 μg protein;

[0100] c) CVB3 in an amount from about 2 μg protein to about 4 μg protein;

[0101] d) CVB4 in an amount from about 1 μg protein to about 2 μg protein; and

[0102] e) CVB5 in an amount from about 1 μg protein to about 2.5 μg protein, with a total amount of protein from about 8 μg protein to about 15 μg protein. The amount of protein can have a volume of from about 75 μL to about 150 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL, or from about 140 μL to about 150 μL). In some cases, the composition comprises the amount of CVB in a volume of 100 μL. In some cases, the composition does not include CBV6.

[0103] In some cases, the compositions of the present disclosure include:

[0104] a) CVB1, the amount of which was 2.8 μg protein;

[0105] b) CVB2, the amount of which was 1.7 μg protein;

[0106] c) CVB3, the amount of which was 2.7 μg protein;

[0107] d) CVB4 in an amount of 1.2 μg protein; and

[0108] e) CVB5 in an amount of 2.3 μg protein, with a total amount of about 10.7 μg protein. The amount of protein can have a volume of from about 75 μL to about 150 μL (e.g., from about 75 μL to about 80 μL, from about 80 μL to about 85 μL, from about 85 μL to about 90 μL, from about 90 μL to about 110 μL, from about 95 μL to about 105 μL, from about 95 μL to about 100 μL, from about 100 μL to about 110 μL, from about 110 μL to about 120 μL, from about 120 μL to about 130 μL, from about 130 μL to about 140 μL, or from about 140 μL to about 150 μL. In some cases, the composition comprises the amount of CVB in a volume of 100 μL. In some cases, the composition does not include CBV6.

[0109] In some cases, the compositions of the present disclosure include:

[0110] a) CVB1 in an amount from about 10 μg protein to about 20 μg protein;

[0111] b) CVB2 in an amount from about 5 μg protein to about 12.5 μg protein;

[0112] c) CVB3 in an amount from about 10 μg protein to about 20 μg protein;

[0113] d) CVB4 in an amount from about 5 μg protein to about 10 μg protein; and

[0114] e) CVB5 in an amount from about 5 μg protein to about 12.5 μg protein, with a total amount of protein from about 35 μg protein to about 75 μg protein. The amount of CVB can have a volume from about 400 μL to about 450 μL, from about 450 μL to about 500 μL, from about 500 μL to about 550 μL, or from about 550 μL to about 600 μL. In some cases, the composition comprises the amount of CVB in a volume of 500 μL. In some cases, the composition does not include CBV6.

[0115] In some cases, the compositions of the present disclosure include:

[0116] a) CVB1, the amount of which was 14 μg protein;

[0117] b) CVB2, the amount of which was 8.5 μg protein;

[0118] c) CVB3, the amount of which was 13.5 μg protein;

[0119] d) CVB4 in an amount of 6 μg protein; and

[0120] e) CVB5 in an amount of 11.5 μg protein, with a total amount of 53.5 μg protein. The amount of CVB can have a volume of from about 400 μL to about 450 μL, from about 450 μL to about 500 μL, from about 500 μL to about 550 μL, or from about 550 μL to about 600 μL. In some cases, the composition comprises the amount of CVB in a volume of 500 μL. In some cases, the composition does not include CBV6.

[0121] The compositions of the present disclosure induce virus neutralizing antibody titers (VNT) from 1 / 8 to 1 / 64,000 when administered to an individual, as determined by a VNT assay. In some cases, this VNT is a peak VNT (e.g., Figure 3 ). In some cases, the compositions of the present disclosure induce about 1 / 2,000 to about 1 / 4,000 of VNT when administered to an individual, as determined by a VNT assay. In some cases, the compositions of the present disclosure induce about 1 / 10 to about 1 / 500 of VNT when administered to an individual, as determined by a VNT assay. In some cases, the compositions of the present disclosure induce about 1 / 500 to about 1 / 1,000 of VNT when administered to an individual, as determined by a VNT assay. In some cases, the compositions of the present disclosure induce about 1 / 1,000 to about 1 / 2,000 of VNT when administered to an individual, as determined by a VNT assay. In some cases, the compositions of the present disclosure induce about 1 / 2,000 to about 1 / 4,000 of VNT when administered to an individual, as determined by a VNT assay. In some cases, the compositions of the present disclosure induce about 1 / 4,000 to about 1 / 8,000 of VNT when administered to an individual, as determined by a VNT assay. In some cases, the compositions of the present disclosure induce about 1 / 8,000 to about 1 / 10,000 of VNT when administered to an individual, as determined by a VNT assay. In some cases, the compositions of the present disclosure induce about 1 / 10,000 to about 1 / 20,000 of VNT when administered to an individual, as determined by a VNT assay.

[0122] As used herein, "virus neutralizing antibody titer" refers to the highest dilution of a sample that still neutralizes the infectivity of the virus in the cell culture. Using a plaque reduction assay, the virus neutralizing titer (VNT) is calculated as the last serum dilution that reduces the number of plaques by at least 80%. See, e.g., Boone and Albrecht (1983) J. Virol. Methods 6:193. Thus, for example, a VNT of 1 / 2,000 refers to the amount of antibody in a sample that no longer neutralizes the CVB in the sample when the sample is diluted beyond 1 / 2,000 ("2,000 VNT"). For example, in FIGS. 2 and 3 , the VNT of the sample is 1 / 2,000, ... Figure 3 In the examples, “2,000” means that a 2000x dilution (referred to as “1 / 2,000” or “2,000 VNT”) is the highest dilution that reduces infection of cells in culture by at least 80%; and “4,000” means that a 4000x dilution (referred to as “1 / 4,000” or “4,000 VNT”) is the highest dilution that reduces infection of cells in culture by at least 80%.

[0123] In some cases, a single dose of the subject composition is administered to an individual. In some cases, 14 days after administration of a single dose of the composition, the VNT for CVB in the individual increases by 8-10 times relative to the control. In some cases, 14 days after administration of a single dose of the composition, the VNT for CVB in the individual increases by 3-10 times relative to the control. The control refers to: i) the VNT for CVB in the individual before administration of a single dose of the composition of the present disclosure; or ii) a reference control level of VNT for CVB.

[0124] In some cases, a first dose of the subject composition is administered to an individual; and a second dose of the subject composition is administered to an individual at a time after the first dose (e.g., a second dose is administered 7 days to 3 weeks, 7 days to 2 weeks, 2 weeks to 1 month, 1 month to 2 months, 2 months to 3 months, or 3 months to 6 months after the first dose). In some cases, a first dose of the subject composition is administered to an individual; and a second dose of the subject composition is administered to an individual 1 month after the first dose. In some cases, a first dose of the subject composition is administered to an individual; and a second dose of the subject composition is administered to an individual 2 months after the first dose. In some cases, a first dose of the subject composition is administered to an individual; and a second dose of the subject composition is administered to an individual 3 months after the first dose. In some cases, 14 days after the second dose of the composition is administered, the VNT for CVB in the individual increases by 8 to 10 times relative to the control. In some cases, 14 days after the second dose of the composition is administered, the VNT for CVB in the individual increases by 3-10 times relative to the control. Control refers to: i) VNT to CVB in an individual prior to administration of a first dose of a composition of the present disclosure; or ii) a reference control level of VNT to CVB.

[0125] Neutralization titers are produced by neutralizing antibodies against CVB, as measured in subject serum. In some cases, the effective dose of the composition of the present disclosure is sufficient to produce a virus neutralization titer (VNT) of at least 100. In some cases, the effective dose of the composition of the present disclosure is sufficient to produce a VNT of 100-500. In some cases, the effective dose of the composition of the present disclosure is sufficient to produce a VNT greater than 500. For example, in some cases, the effective dose of the composition of the present disclosure is sufficient to produce 500-1,000 VNT. As another example, in some cases, the effective dose of the composition of the present disclosure is sufficient to produce 1000-10,000 VNT. In some cases, an effective dose of a composition of the present disclosure is sufficient to produce 1000-2000, 1000-3000, 1000-4000, 1000-5000, 1000-6000, 1000-7000, 1000-8000, 1000-9000, 1000-10,000, 2000-3000, 2000-4000, 2000-5000, 2000-6000, 2000-7000, 2000-8000, 2000-9000, 2000-10,000, 3000-4000, 3000-5000, 3000-6000, 3000-7000, 3000-8000. 、3000-9000、3000-10,000、4000-5000、4000-6000、4000-7000、4000-8000、4000-9000、4000-10,000、5000-6000、5000-7000、5000-8000、5000-9000 ; 5000-10,000, 6000-7000, 6000-8000, 6000-9000, 6000-10,000, 7000-8000, 7000-9000, 7000-10,000, 8000-9000, 8000-10,000 or 9000-10,000 VNT. In some cases, an effective dose of a composition of the present disclosure is sufficient to produce 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 11000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19000, 20,000 or more VNT. In some cases, VNT is produced 1-72 hours after administration.For example, VNTs may be produced 1-10, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-72, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10-72, 20-30, 20-40, 20-50, 20-60, 20-70, 20-72, 30-40, 30-50, 30-60, 30-70, 30-72, 40-50, 40-60, 40-70, 40-72, 50-60, 50-70, 50-72, 60-70, 60-72, or 70-72 hours after administration. 65,66,67,68,69,70,71, or 72 hours after administration. In some cases, VNTs are produced within 14 days of administering a composition of the present disclosure. In some cases, VNTs are produced within 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days of administering a composition of the disclosure.

[0126] In some cases, after administration of one or more doses of the CVB composition of the present disclosure, 1 / 8 to 1 / 64,000 of the VNT is maintained for a period of at least 24 weeks, at least 32 weeks, at least 40 weeks, at least 52 weeks, or more than 52 weeks. In some cases, the VNT comprises IgG isotype antibodies (e.g., the VNT comprises at least 50%, at least 60%, at least 75%, at least 85%, or more than 85% IgG isotype antibodies). In some cases, the VNT comprises IgG isotype antibodies, IgM isotype antibodies, and IgA isotype antibodies.

[0127] VNT can be determined using a VNT assay (also referred to as a "plaque reduction assay"). The presence of neutralizing antibodies blocks the infectivity of the virus to cells. In order to perform a VNT assay, serum obtained from an individual is diluted to a variety of degrees. The diluted serum is mixed with an amount of infectious virus optimized for each viral serotype (e.g., 30-100 plaque forming units (PFU) of virus, where PFU represents one infectious virus particle), and the mixture is incubated at room temperature for a period of time (e.g., first incubated at 37° C. for 60 min, followed by overnight incubation (approximately 18 hours)). After the incubation period, the mixture is added to a monolayer of cells (e.g., green monkey kidney cells (GMK-AH-1 cells; RRID: CVCL_L878), and the cell monolayer is incubated with the mixture for a certain period of time (e.g., 40-48 hours). After this incubation, the number of virus-induced plaques on the monolayer is counted, for example, after staining the cells or by microscopic examination of the cells. A mixture of virus and hyperimmune serum raised against the enterovirus serotype in question (e.g., serum raised in monkeys or horses) is used as a positive control for specific neutralization of each serotype. Virus without serum is used as a negative control. The neutralization titer (VNT) is calculated as the last serum dilution that reduces the number of plaques by at least 80%. See, e.g., Boone and Albrecht (1983) J. Virol. Methods 6: 193.

[0128] The compositions of the present disclosure may include whole CVB viruses that have been inactivated for infectiousness; or subunit vaccines containing certain antigenic structures, proteins or peptides of the virus, or a combination thereof (such as virus-like particles); or fragments of viral RNA or cDNA encoding the whole virus or individual viral proteins of the virus or an inactivated form.

[0129] In some cases, the compositions of the present disclosure include components of CVB. The "components" can be immunogenic polypeptides of the virus, such as subunits thereof (including chimeric subunits), or nucleic acid fragments, such as parts of the viral genome. The components can also be recombinantly or synthetically produced or modified.

[0130] Subunit vaccines can be composed of purified or recombinant viral proteins, synthetic peptides corresponding to viral antigenic epitopes, VLPs, or empty viral capsids produced during infection but lacking the viral genome. These subunit vaccines can be administered as is or conjugated to haptens or carriers (e.g., ISCOM particles, chitosan, TLR agonists, biodegradable microparticles).

[0131] As described above, the compositions of the present disclosure may include CVB subunits, for example, one or more CVB polypeptides. Polypeptides encoded by CVB include VP1, VP2, VP3, VP4, 2A, 2B, 2C, 3A, 3B, 3C, and 3D. For example, a composition may include one or more CVB polypeptides, wherein the one or more CVB polypeptides include CVB polypeptides that are identical to a complete viral polyprotein (e.g., Figure 1 The amino acid sequence of the CVB4 polyprotein shown in ) or any polypeptide derived from the precursor polyprotein has an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% amino acid sequence identity. For example, after the polyprotein matures, Figure 1 The first 73 amino acids of the CVB4 polyprotein in the CBV4 VP4 component of the virus form. The composition can include any CBV4 VP4 polypeptide, the polypeptide comprising an amino acid sequence having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99% or 100% amino acid sequence identity with the complete amino acid sequence of CBV4 VP4 or with a polypeptide fragment of the mature form of CBV4 VP4. VLPs can be formed using full-length viral proteins, truncated forms of full-length viral proteins, or fusion proteins containing a portion of viral proteins.

[0132] As described above, compositions suitable for administration to individuals in need may include one or more nucleic acids comprising one or more nucleotide sequences encoding one or more CVB polypeptides. Suitable nucleic acids include recombinant expression vectors. In some cases, the one or more nucleic acids are recombinant expression vectors comprising one or more nucleotide sequences encoding one or more CVB polypeptides. In some cases, the recombinant expression vector is a DNA or RNA molecule comprising a nucleotide sequence encoding a target gene product (e.g., RNA or polypeptide). Recombinant expression vectors include viral expression vectors (e.g., based on the following viral vectors: vaccinia virus; poliovirus; adenovirus, adeno-associated virus (AAV), lentivirus, SV40, herpes simplex virus, human immunodeficiency virus (HIV), retrovirus, etc.). In some cases, the recombinant expression vector is a recombinant lentiviral vector. In some cases, the recombinant expression vector is a recombinant HIV vector. In some cases, the recombinant expression vector is a recombinant adenoviral vector. In some cases, the recombinant expression vector is a recombinant AAV vector. In some cases, the one or more nucleotide sequences encoding the one or more CVB polypeptides are operably linked to one or more transcription control elements (e.g., promoters). In some cases, the nucleotide sequence encoding the gene product of interest is operably linked to a promoter that is functional in mammalian cells (eg, muscle cells, epithelial cells, dendritic cells, antigen presenting cells, etc.).

[0133] Suitable nucleic acids include mRNA. Therefore, in some cases, the composition suitable for application to an individual in need includes one or more RNA molecules (e.g., mRNA), and the one or more RNA molecules include one or more nucleotide sequences encoding one or more CVB polypeptides. In some cases, the one or more RNA molecules include at least one 5' cap structure and / or 5' untranslated region (5'UTR). In some cases, the one or more RNA molecules also include 3'UTR and / or 3' tailing sequence (e.g., poly (adenosine) (poly A) sequence). The example of 5' cap structure includes inosine, N1-methyl-guanosine, 2' fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine and 2-azido-guanosine. In some cases, the one or more RNA molecules include one or more of the following: nucleoside base modification, sugar modification and backbone modification. In some cases, in addition to the one or more RNA molecules, the composition further comprises one or both of the following: a) a polymer (e.g., polyethylene glycol, polyglycolide, polyvinyl alcohol, polyvinyl pyrrolidone, polylactic acid, poly(lactide-co-glycolide) (PLGA), polycaprolactone, polysorbate, polyethylene oxide, polypropylene oxide, poly(ethylene oxide-co-propylene oxide), poloxamers, poloxamines, poly(oxyethylated) glycerol, poly(oxyethylated) sorbitol, poly(oxyethylated) glucose, polyethyleneimine, polyamidoamine (PAMAM) dendrimers, and block copolymers poly(ethylene glycol)-block-poly(lactic acid-co-glycolic acid) (PEG-b-PLGA)); and b) a lipid.

[0134] In some cases, a composition suitable for administration to an individual in need comprises one or more RNA molecules (e.g., mRNA) comprising one or more nucleotide sequences encoding one or more CVB polypeptides. In some cases, the one or more RNA molecules are administered to an individual in need in an amount such that at least 2 hours after administration, the level of the one or more encoded CVB polypeptides in the serum of the individual is at least 50 pg / mL. In some cases, the one or more RNA molecules are administered to an individual in need in an amount such that the level of the one or more encoded CVB polypeptides in the serum of the individual remains above 50 pg / mL for at least 72 hours after administration.

[0135] In some cases, each of the one or more mRNAs is administered in an amount from about 1 μg to about 200 μg, for example, from about 1 μg to about 5 μg, from about 5 μg to about 10 μg, from about 10 μg to about 15 μg, from about 15 μg to about 20 μg, from about 20 μg to about 25 μg, from about 25 μg to about 30 μg, from about 30 μg to about 40 μg, from about 40 μg to about 50 μg, from about 50 μg to about 60 μg, from about 60 μg to about 70 μg, from about 70 μg to about 80 μg, from about 80 μg to about 90 μg, from about 90 μg to about 100 μg, from about 100 μg to about 125 μg, from about 125 μg to about 150 μg, from about 150 μg to about 175 μg, or from about 175 μg to about 200 μg.

[0136] For example, in some cases, the compositions of the present disclosure include nucleic acids (e.g., mRNAs) encoding CVB1, CVB2, CVB3, CVB4, and CVB5, but not CVB6, wherein each of the mRNAs is present in the composition in an amount from about 1 μg to about 200 μg, e.g., from about 1 μg to about 5 μg, from about 5 μg to about 10 μg, from about 10 μg to about 15 μg, from about 15 μg to about 20 μg, from about 20 μg to about 25 μg, μg, from about 25 μg to about 30 μg, from about 30 μg to about 40 μg, from about 40 μg to about 50 μg, from about 50 μg to about 60 μg, from about 60 μg to about 70 μg, from about 70 μg to about 80 μg, from about 80 μg to about 90 μg, from about 90 μg to about 100 μg, from about 100 μg to about 125 μg, from about 125 μg to about 150 μg, from about 150 μg to about 175 μg, or from about 175 μg to about 200 μg.

[0137] In some cases, the compositions of the present disclosure include nucleic acids (e.g., mRNA) encoding polypeptides of only a single CVB serotype. For example, in some cases, the compositions of the present disclosure include nucleic acids encoding only CVB1 polypeptides. As another example, in some cases, the compositions of the present disclosure include nucleic acids encoding only CVB2 polypeptides. As another example, in some cases, the compositions of the present disclosure include nucleic acids encoding only CVB3 polypeptides. As another example, in some cases, the compositions of the present disclosure include nucleic acids encoding only CVB4 polypeptides. As another example, in some cases, the compositions of the present disclosure include nucleic acids encoding only CVB5 polypeptides. In some cases, the nucleic acid encoding a polypeptide of only a single CVB serotype is an mRNA, and the mRNA is present in the composition in an amount from about 1 μg to about 200 μg, e.g., from about 1 μg to about 5 μg, from about 5 μg to about 10 μg, from about 10 μg to about 15 μg, from about 15 μg to about 20 μg, from about 20 μg to about 25 μg, from about 25 μg to about 30 μg, from about 30 μg to about 150 μg. about 40 μg, from about 40 μg to about 50 μg, from about 50 μg to about 60 μg, from about 60 μg to about 70 μg, from about 70 μg to about 80 μg, from about 80 μg to about 90 μg, from about 90 μg to about 100 μg, from about 100 μg to about 125 μg, from about 125 μg to about 150 μg, from about 150 μg to about 175 μg, or from about 175 μg to about 200 μg.

[0138] In some cases, the compositions of the present disclosure include nucleic acids (e.g., mRNAs) encoding CVB polypeptides of only two different serotypes (e.g., CVB1 and CVB2; CVB1 and CVB3; CVB1 and CVB4; CVB1 and CVB5; CVB2 and CVB3; CVB2 and CVB4; CVB2 and CVB5; CVB3 and CVB4; CVB3 and CVB5; or CVB4 and CVB5), and do not include nucleic acids encoding CVB polypeptides of any other serotype. In some cases, the nucleic acids encoding polypeptides of only two CVB serotypes are mRNAs, and each of the mRNAs is present in the composition in an amount from about 1 μg to about 200 μg, e.g., from about 1 μg to about 5 μg, from about 5 μg to about 10 μg, from about 10 μg to about 15 μg, from about 15 μg to about 20 μg, from about 20 μg to about 25 μg, from about 25 μg to about 30 μg, from about 3 From about 0 μg to about 40 μg, from about 40 μg to about 50 μg, from about 50 μg to about 60 μg, from about 60 μg to about 70 μg, from about 70 μg to about 80 μg, from about 80 μg to about 90 μg, from about 90 μg to about 100 μg, from about 100 μg to about 125 μg, from about 125 μg to about 150 μg, from about 150 μg to about 175 μg, or from about 175 μg to about 200 μg.

[0139] In some cases, the compositions of the present disclosure include nucleic acids (e.g., mRNA) encoding CVB polypeptides of only three different serotypes (e.g., CVB1, CVB2, and CVB3; CVB1, CVB2, and CVB4; CVB1, CVB2, and CVB5; CVB1, CVB3, and CVB4; CVB1, CVB3, and CVB5; CVB2, CVB3, and CVB4; CVB2, CVB3, and CVB5; CVB3, CVB4, and CVB5), and do not include nucleic acids encoding CVB polypeptides of any other serotype. In some cases, the nucleic acid encoding the polypeptides of only three CVB serotypes is an mRNA, and each of the mRNAs is present in the composition in an amount of from about 1 μg to about 200 μg, e.g., from about 1 μg to about 5 μg, from about 5 μg to about 10 μg, from about 10 μg to about 15 μg, from about 15 μg to about 20 μg, from about 20 μg to about 25 μg, from about 25 μg to about 30 μg, from about 3 From about 0 μg to about 40 μg, from about 40 μg to about 50 μg, from about 50 μg to about 60 μg, from about 60 μg to about 70 μg, from about 70 μg to about 80 μg, from about 80 μg to about 90 μg, from about 90 μg to about 100 μg, from about 100 μg to about 125 μg, from about 125 μg to about 150 μg, from about 150 μg to about 175 μg, or from about 175 μg to about 200 μg.

[0140] In some cases, a composition of the disclosure includes nucleic acids encoding CVB polypeptides of only 4 different serotypes (e.g., a composition may exclude nucleic acids encoding polypeptides of: CVB3 and CVB6; CVB4 and CVB6; CVB5 and CVB6; any other combination of 2 CVB serotypes).

[0141] The above CVB, subunit, VLP or nucleic acid can be formulated into a pharmaceutical composition, which, in addition to the active ingredient that triggers immune stimulation, can also contain a pharmaceutically acceptable excipient, carrier, hapten and / or adjuvant. Excipients, carriers, haptens and adjuvants can include, for example, phenoxyethanol, magnesium chloride, sucrose, thimerosal, formaldehyde, phenol, antibiotics (preservatives) or aluminum salts, polymer microparticles, ISCOM particles, carrier proteins (e.g., cholera toxin), liposomes, protein micelles (haptens / adjuvants) or TLR agonists.

[0142] The CVB composition may include an adjuvant (e.g., an immunostimulatory amount of an adjuvant). The CVB composition may include an immunostimulatory amount of an adjuvant. Examples of known suitable adjuvants for use in humans include, but are not necessarily limited to, alum, aluminum phosphate, aluminum hydroxide, MF59 (4.3% w / v squalene, 0.5% w / v Tween 80 TM, 0.5% w / w Span 85), CpG-containing nucleic acids (wherein cytosine is unmethylated), QS21, monophosphoryl lipid A (MPL), 3-Q-deacylated-4'-monophosphoryl lipid A (3DMPL), extracts from Aquilla, immunostimulatory complexes (ISCOM; a complex of cholesterol, phospholipids, and Quillaja saponins), LT / CT mutants, poly(D,L-glycolide-co-lactide) (PLG) microparticles, Quil A, interleukins, etc. For experimental animals, one can use Freund's incomplete adjuvant or Freund's complete adjuvant. Also suitable for use are N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutamido-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI (which contains three components extracted from bacteria in a 2% squalene / Tween 80 emulsion: monophosphoryl lipid A, bimycolic acid trehalose esters, and a cell wall skeleton (MPL+TDM+CWS)). As another example, the adjuvant may include another virus (other than CVB) that is combined with the compositions of the disclosure, or serves as a carrier for CVB proteins displayed by a non-CVB virus.

[0143] Other exemplary adjuvants that enhance the effectiveness of the composition include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulants, such as muramyl peptides (see below) or bacterial cell wall components), such as (a) MF59 TM (see, e.g., WO 90 / 14837), which contains 5% squalene, 0.5% Tween 80 and 0.5% Span 85 (optionally containing MTP-PE) and is formulated into submicron particles using a microfluidizer, (b) SAF, which contains 10% squalane, 0.4% Tween 80, 5% pluronic blocked polymer L121 and thr-MDP, which is microfluidized into a submicron emulsion or vortexed to produce an emulsion with larger particle size, and (c) RIBI TMadjuvant system (RAS), (Ribi Immunochem, Hamilton, Montana), which contains 2% squalene, 0.2% Tween 80 and one or more bacterial cell wall components (such as monophosphoryl lipid A (MPL), dimycolic acid trehalose (TDM) and cell wall skeleton (CWS), such as MPL + CWS (Detox™)); (2) saponin adjuvants such as QS21 or Stimulon TM(Cambridge Bioscience, Worcester, MA; purified Quillaja saponaria extract) or particles produced therefrom, such as ISCOM (immunostimulatory complex), which may not contain additional detergents, such as WO 00 / 07621; (3) complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA); (4) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO 99 / 44636)), interferons (e.g., gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL), such as GB-2220221, EP-A-0689454, optionally in the substantial absence of alum when used with pneumococcal saccharides, such as WO 00 / 56358; (6) 3dMPL in combination with, for example, QS21 and / or an oil-in-water emulsion (see, for example, EP-A-0835318, EP-A-0735898, EP-A-0761231); (7) oligonucleotides comprising a CpG motif containing at least one CG dinucleotide, wherein the cytosine is unmethylated (see, for example, WO 96 / 02555, WO 98 / 16247, WO 98 / 18810, WO 98 / 40100, WO 98 / 55495, WO 98 / 37919 and WO 98 / 52581); (8) polyoxyethylene ethers or polyoxyethylene esters (see, for example, WO 99 / 52549); (9) polyoxyethylene sorbitan ester surfactants in combination with octoxynol (WO 01 / 21207), or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional nonionic surfactant (such as octoxynil) (WO 01 / 21152); (10) saponin and immunostimulatory oligonucleotides (e.g., CpG oligonucleotides) (WO 00 / 62800); (11) immunostimulatory agents and metal salt particles (see, e.g., WO 00 / 23105); (12) saponin and oil-in-water emulsions (see, e.g., WO 99 / 11241); (13) saponin (e.g., QS21) + 3dMPL + IM2 (optionally including sterols) (see, e.g., WO 98 / 57659); (14) other substances used as immunostimulants to enhance the efficacy of the composition.Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutamine-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc. Also suitable for use is Matrix-M. TM Matrix-M TM is an adjuvant comprising 40 nm nanoparticles containing quillaja saponins, cholesterol, and phospholipids. Adjuvants suitable for administration to humans are of particular interest. In some cases, the adjuvant is a CD4 + Adjuvants for the response of T helper cells to immunogens. Also suitable for use are polyinosine:cytosine (poly I:C) nucleic acids. Poly I:C is a synthetic double-stranded RNA. Also suitable for use are cyclic dinucleotide activators of the STING pathway. Examples of suitable cyclic dinucleotide adjuvants include, but are not limited to: 1) bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP); 2) bis-(3',5')-cyclic dimeric guanosine monophosphate (c-di-GMP); and bis-(3',5')-cyclic dimeric inosine monophosphate (c-di-IMP). Also suitable for use is poly (I:C).

[0144] The effectiveness of an adjuvant can be determined by one or more of the following: i) measuring the amount of antibodies against the immunogenic antigen or its antigenic epitope (e.g., using a VNT assay as described above); ii) measuring the response of cytotoxic T lymphocytes against the antigen; and iii) measuring the response of helper T cells against the antigen.

[0145] The compositions of the present disclosure may include pharmaceutically acceptable excipients, and a variety of the excipients are known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients have been fully described in various publications, including, for example, "Remington: The Science and Practice of Pharmacy", 19th edition (1995) or the latest edition, Mack Publishing Co; A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) HC Ansel et al., ed. 7th edition, Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) AK Kibbe et al., ed., 3rd edition Amer. Pharmaceutical Assoc.

[0146] The pharmaceutical composition may include a pharmaceutically acceptable excipient. In some cases, the subject pharmaceutical composition will be suitable for administration to a subject, e.g., will be sterile. For example, in some cases, the subject pharmaceutical composition will be suitable for administration to a human subject, e.g., wherein the composition is sterile and does not contain detectable pyrogens and / or other toxins.

[0147] The protein composition may include other components, such as pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, etc. The composition may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusters and buffers, toxicity adjusters, etc., for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, hydrochloride, sulfate, solvate (e.g., mixed ion salts, water, organic matter), hydrate (e.g., water), etc.

[0148] In some cases, the composition of the present disclosure is a liquid composition. Thus, the present disclosure provides a composition (e.g., a liquid composition, including a pharmaceutical composition) comprising CVB as described above. In some cases, the composition of the present disclosure comprises: a) CVB as described above; and b) saline (e.g., 0.9% NaCl). In some cases, the composition is sterile. In some cases, the composition is suitable for administration to a human subject, e.g., wherein the composition is sterile and does not contain detectable pyrogens and / or other toxins. Thus, the present disclosure provides a composition comprising: a) CVB as described above; and b) saline (e.g., 0.9% NaCl), wherein the composition is sterile and does not contain detectable pyrogens and / or other toxins. Methods of inducing an immune response

[0149] The present disclosure provides methods for inducing an immune response against CVB in an individual. The method comprises administering an effective amount of a composition of the present disclosure to an individual in need thereof. The composition of the present disclosure is hereinafter referred to as an "immunogenic composition". The present disclosure provides methods for reducing the likelihood that an individual will develop an acute CVB infection. The method comprises administering an effective amount of a composition of the present disclosure to an individual in need thereof. The present disclosure provides methods for reducing the likelihood that an individual will develop a CVB infection-related disease and / or symptoms of a CVB infection. The method comprises administering an effective amount of a composition of the present disclosure to an individual in need thereof.

[0150] The immunogenic compositions described above can be administered by injection (eg, intramuscularly or subcutaneously), parenterally, orally, intradermally, transdermally, sublingually, intranasally, nasopharyngeally, via inhalation, or rectally.

[0151] In some cases, a primary immunization-boost vaccine regimen is used. In some cases, a first (primary immunization) immunogenic composition is administered, and after a certain period of time, a second (boost) immunogenic composition is administered. The second immunogenic composition can be administered in a time period of 1 day to 1 year after the first immunogenic composition is administered. For example, the second immunogenic composition can be administered in the following time period after the first immunogenic composition is administered: 1 day to 1 week, 1 week to 2 weeks, 2 weeks to 1 month, 1 month to 2 months, 2 months to 6 months, or 6 months to 1 year.

[0152] The methods of the present disclosure can induce an immune response against CVB in an individual. For example, the methods of the present disclosure can induce an immune response against one or more of CVB1, CVB2, CVB3, CVB4, and CVB5 in an individual. In some cases, the methods of the present disclosure can induce an immune response against CVB1, CVB2, CVB3, CVB4, and CVB5 in an individual.

[0153] In some cases, the methods of the present disclosure can reduce the likelihood of acute CVB infection. In some cases, the methods of the present disclosure can reduce the likelihood that an individual will develop a CVB infection-related disease (e.g., CVB-induced gastrointestinal disease, myocarditis, pneumonia, aseptic meningitis, encephalitis, or hepatitis). In some cases, the methods of the present disclosure can improve one or more adverse symptoms of CVB infection. In some cases, the methods of the present disclosure treat one or more of CVB-induced gastrointestinal disease, myocarditis, pneumonia, aseptic meningitis, encephalitis, and hepatitis.

[0154] In some cases, where an individual to whom an immunogenic composition of the disclosure is to be administered has a greater risk of developing type 1 diabetes (T1D) than the general population, the methods of the disclosure can reduce the likelihood that the individual will develop T1D.

[0155] In some cases, where an individual to whom an immunogenic composition of the disclosure is to be administered is at greater risk for developing celiac disease than the general population, the methods of the disclosure can reduce the likelihood that the individual will develop chylititis. Subjects suitable for treatment

[0156] In some cases, the individual suitable for treatment according to the present disclosure is 1 month to 3 months old (e.g., 1 month, 2 months, or 3 months old). In some cases, the age of the individual suitable for treatment according to the present disclosure is 3 months to 5 years old. In some cases, the age of the individual suitable for treatment according to the present disclosure is 3 months to 6 months, 6 months to 1 year old, 1 year to 2 years old, or 2 years to 5 years old. In some cases, the age of the individual suitable for treatment according to the present disclosure is 5 years old to 11 years old. In some cases, the age of the individual suitable for treatment according to the present disclosure is 12 years old to 17 years old. In some cases, the age of the individual suitable for treatment according to the present disclosure is 18 years old to 25 years old. In some cases, the individual suitable for treatment according to the present disclosure is greater than 25 years old.

[0157] In some cases, the subject is older than 6 years old, two years old or older, six years old or older, 12 years old or older, 18 years old or older, 30 years old or older, between about 6 and 12 years old, between about 6 and about 30 years old, between about 12 and about 30 years old, or between about 18 and about 30 years old. In some cases, the subject is a pregnant woman.

[0158] In some cases, individuals suitable for treatment according to the present disclosure are immunonaive with respect to CVB; that is, the individual has low or undetectable neutralizing antibodies against CVB. In some cases, individuals suitable for treatment according to the present disclosure have previously been exposed to (e.g., via natural infection) CVB and have a detectable antibody titer against CVB.

[0159] In some cases, the individual has a risk of developing type 1 diabetes (T1D) (e.g., a risk greater than the general population). Individuals with a risk of developing T1D (e.g., a risk greater than the general population) include individuals who have been genetically determined to have an increased risk of developing T1D, for example, individuals with an HLA-conferring T1D susceptibility, particularly carriers of HLA DR3 and / or DR4 alleles. Individuals with a risk of developing T1D (e.g., a risk greater than the general population) include mothers or children with an HLA-conferring T1D disease susceptibility, particularly carriers of HLA DR3 and / or DR4 alleles; individuals whose first or second degree relatives have T1D; and individuals (e.g., children) who test positive for two or more diabetes-related autoantibodies. In some cases, the subject method reduces the likelihood that an individual will develop T1D.

[0160] In some cases, the individual is at risk for developing celiac disease (e.g., at a greater risk than the general population). Such individuals include individuals with a genetic predisposition to developing celiac disease; and individuals who test positive for celiac disease-associated autoantibodies. In some cases, the individual is a carrier of an HLA-DR3 allele. Examples of non-limiting aspects of the present disclosure Aspect Set A

[0161] The various aspects of the above-described inventive subject matter (including embodiments) may be beneficial alone or in combination with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the present disclosure are provided below. As will be clear to those skilled in the art upon reading the present disclosure, each of the separately numbered aspects may be used or combined with any of the previously or below separately numbered aspects. This is intended to provide support for all such combinations of aspects, and is not limited to the combinations of aspects explicitly provided below:

[0162] Aspect 1. A composition comprising two to five serotypes of Coxsackievirus B (CVB), wherein the CVB is in the form of an inactivated viral particle (IVP), a virus-like particle (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising a nucleotide sequence encoding the one or more CVB polypeptides, wherein the composition comprises:

[0163] A) Two or more of the following:

[0164] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0165] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0166] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0167] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0168] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0169] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0170] The volume is 100 μL; or

[0171] B) Two or more of the following:

[0172] a) CVB1, the amount of which ranges from 1.0x10 8 IVP to 2.5x10 8 IVPs;

[0173] b) CVB2, the amount of which is from 5.0x10 7 IVP to 1.5x10 8 IVPs;

[0174] c) CVB3, the amount of which is from 5.0x10 8 IVP to 1.5x10 9 IVPs;

[0175] d) CVB4, the amount of which is from 1.0x10 8 IVP to 2.5x10 8 IVPs; and

[0176] e) CVB5, the amount of which is from 2.0x10 8IVP to 4.0x10 8 IVPs,

[0177] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0178] The volume is 500 μL,

[0179] wherein the composition does not include CVB6.

[0180] Aspect 2. The composition according to aspect 1, wherein the composition comprises:

[0181] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0182] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0183] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0184] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0185] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0186] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0187] The volume is 100 μl.

[0188] Aspect 3. The composition according to aspect 2, wherein the composition comprises:

[0189] a) CVB1, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs;

[0190] b) CVB2, the amount of which is from 1.0x10 7 IVP to 2.0x10 7 IVPs;

[0191] c) CVB3, the amount of which is from 1.0x10 8 IVP to 2.0x10 8 IVPs;

[0192] d) CVB4, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs; and

[0193] e) CVB5, the amount of which is from 6.0x10 7 IVP to 6.0x10 7 IVPs,

[0194] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

[0195] Aspect 4. A composition comprising two to five serotypes of Coxsackievirus B (CVB), wherein the CVB is in the form of inactivated viral particles (IVPs), CVB virus-like particles (VLPs), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition induces a virus neutralizing antibody titer (VNT) of 1 / 8 to 1 / 64,000 when administered to an individual, as determined by a VNT assay, wherein the composition does not include CVB6.

[0196] Aspect 5. The composition according to aspect 4, wherein the composition comprises two to five serotypes of CVB, wherein the CVB is in the form of inactivated viral particles (IVP), wherein the composition comprises:

[0197] A) Two or more of the following:

[0198] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0199] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0200] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0201] d) CVB4, the amount of which is from 2.0x10 7IVP to 5.0x10 7 IVPs; and

[0202] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0203] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0204] The volume is 100 μL; or

[0205] B) Two or more of the following:

[0206] a) CVB1, the amount of which ranges from 1.0x10 8 IVP to 2.5x10 8 IVPs;

[0207] b) CVB2, the amount of which is from 5.0x10 7 IVP to 1.5x10 8 IVPs;

[0208] c) CVB3, the amount of which is from 5.0x10 8 IVP to 1.5x10 9 IVPs;

[0209] d) CVB4, the amount of which is from 1.0x10 8 IVP to 2.5x10 8 IVPs; and

[0210] e) CVB5, the amount of which is from 2.0x10 8 IVP to 4.0x10 8 IVPs,

[0211] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0212] The volume is 500 μL.

[0213] Aspect 6. The composition according to aspect 5, wherein the composition comprises:

[0214] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0215] b) CVB2, the amount of which is from 1.0x10 7IVP to 3.0x10 7 IVPs;

[0216] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0217] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0218] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0219] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

[0220] Aspect 7. The composition according to aspect 6, wherein the composition comprises:

[0221] a) CVB1, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs;

[0222] b) CVB2, the amount of which is from 1.0x10 7 IVP to 2.0x10 7 IVPs;

[0223] c) CVB3, the amount of which is from 1.0x10 8 IVP to 2.0x10 8 IVPs;

[0224] d) CVB4, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs; and

[0225] e) CVB5, the amount of which is from 6.0x10 7 IVP to 6.0x10 7 IVPs,

[0226] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

[0227] Aspect 8. The composition according to any one of aspects 1-7, wherein the IVP is formalin inactivated.

[0228] Aspect 9. The composition according to any one of aspects 1-8, wherein the composition comprises an adjuvant.

[0229] Aspect 10. The composition according to any one of aspects 1-8, comprising saline.

[0230] Aspect 11. A method of inducing an immune response against Coxsackievirus B (CVB) in an individual, the method comprising administering to the individual a composition according to any one of aspects 1-10.

[0231] Aspect 12. The method according to aspect 11, wherein the composition is administered intramuscularly.

[0232] Aspect 13. The method according to aspect 11, wherein the composition is administered subcutaneously.

[0233] Aspect 14. A method of reducing the likelihood that an individual will develop an acute coxsackievirus B (CVB) infection, the method comprising administering to the individual a composition according to any one of aspects 1-10.

[0234] Aspect 15. The method according to any one of Aspects 11-14, wherein the individual is a neonate.

[0235] Aspect 16. The method according to any one of aspects 11-14, wherein the individual is a pregnant woman.

[0236] Aspect 17. The method according to any one of aspects 11-14, wherein the individual has an increased risk of developing type 1 diabetes.

[0237] Aspect 18. The method according to any one of aspects 11-14, wherein the subject has an increased risk of developing celiac disease.

[0238] Aspect 19. The method according to any one of aspects 11 to 14, wherein the individual is a carrier of the HLADR3 and / or HLADR4 alleles.

[0239] Aspect 20. The method according to any one of aspects 11-14, wherein prior to said administering, the individual is seropositive for viral neutralization titers against one or more of CVB1, CVB2, CVB3, CVB4 and CVB5.

[0240] Aspect 21. The method according to any one of aspects 11-14, wherein prior to said administering, said individual is seronegative for viral neutralization titers against one or more of CVB1, CVB2, CVB3, CVB4 and CVB5. Aspect Set B

[0241] The various aspects of the above-described inventive subject matter (including embodiments) may be beneficial alone or in combination with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the present disclosure are provided below. As will be clear to those skilled in the art upon reading the present disclosure, each of the separately numbered aspects may be used or combined with any of the previously or below separately numbered aspects. This is intended to provide support for all such combinations of aspects, and is not limited to the combinations of aspects explicitly provided below:

[0242] Aspect 1. A composition comprising two to five serotypes of Coxsackievirus B (CVB), wherein the CVB is in the form of an inactivated viral particle (IVP), a virus-like particle (VLP), one or more CVB polypeptides, or one or more nucleic acids comprising a nucleotide sequence encoding the one or more CVB polypeptides, wherein the composition comprises:

[0243] A) Two or more of the following:

[0244] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0245] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0246] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0247] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0248] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0249] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0250] The volume is 100 μL; or

[0251] B) Two or more of the following:

[0252] a) CVB1, the amount of which ranges from 1.0x10 8 IVP to 2.5x10 8 IVPs;

[0253] b) CVB2, the amount of which is from 5.0x10 7 IVP to 1.5x10 8 IVPs;

[0254] c) CVB3, the amount of which is from 5.0x10 8 IVP to 1.5x10 9 IVPs;

[0255] d) CVB4, the amount of which is from 1.0x10 8 IVP to 2.5x10 8 IVPs; and

[0256] e) CVB5, the amount of which is from 2.0x10 8 IVP to 4.0x10 8 IVPs,

[0257] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0258] The volume is 500 μL; or

[0259] C) Two or more of the following:

[0260] a) CVB1 protein in an amount ranging from 1 μg to 50 μg;

[0261] b) CVB2 protein in an amount ranging from 1 μg to 50 μg;

[0262] c) CVB3 protein in an amount ranging from 1 μg to 50 μg;

[0263] d) CVB4 protein in an amount ranging from 1 μg to 50 μg; and

[0264] e) CVB5 protein in an amount of from 1 μg to 50 μg,

[0265] wherein the composition does not include CVB6.

[0266] Aspect 2. The composition according to aspect 1, wherein the composition comprises:

[0267] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0268] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0269] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0270] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0271] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0272] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0273] The volume is 100 μl.

[0274] Aspect 3. The composition according to aspect 2, wherein the composition comprises:

[0275] a) CVB1, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs;

[0276] b) CVB2, the amount of which is from 1.0x10 7 IVP to 2.0x10 7 IVPs;

[0277] c) CVB3, the amount of which is from 1.0x10 8 IVP to 2.0x10 8 IVPs;

[0278] d) CVB4, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs; and

[0279] e) CVB5, the amount of which is from 6.0x10 7 IVP to 6.0x10 7 IVPs,

[0280] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

[0281] Aspect 4. The composition according to aspect 1, wherein the composition comprises:

[0282] a) CVB1, the amount is 3.3x10 7 IVPs;

[0283] b) CVB2, the amount of which is 1.1x10 7 IVPs;

[0284] c) CVB3, the amount of which is 1.5x10 8 IVPs;

[0285] d) CVB4, the amount is 3.2x10 7 IVPs; and

[0286] e) CVB5, the amount of which is 6.3x10 7 IVPs,

[0287] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0288] The volume is 100 μl.

[0289] Aspect 5. The composition according to aspect 1, wherein the composition comprises:

[0290] a) CVB1, the amount is 1.6x10 8 IVPs;

[0291] b) CVB2, the amount of which is 5.5x10 7 IVPs;

[0292] c) CVB3, the amount of which is 7.5x10 8 IVPs;

[0293] d) CVB4, the amount is 1.6x10 8 IVPs; and

[0294] e) CVB5, the amount of which is 3.1x10 8 IVPs,

[0295] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0296] The volume is 500 μL.

[0297] Aspect 6. The composition according to aspect 1, wherein the composition comprises:

[0298] a) CVB1 protein, the amount of which was 2.8 μg;

[0299] b) CVB2 protein, the amount of which was 1.7 μg;

[0300] c) CVB3 protein, the amount of which was 2.7 μg;

[0301] d) CVB4 protein in an amount of 1.2 μg; and

[0302] e) CVB5 protein, the amount of which was 2.3 μg,

[0303] The volume is 100 μl.

[0304] Aspect 7. The composition according to aspect 1, wherein the composition comprises:

[0305] a) CVB1 protein, the amount of which was 14 μg;

[0306] b) CVB2 protein, the amount of which was 8.5 μg;

[0307] c) CVB3 protein, the amount of which was 13.5 μg;

[0308] d) CVB4 protein, in an amount of 6.0 μg; and

[0309] e) CVB5 protein, the amount of which was 11.5 μg,

[0310] The volume is 500 μl.

[0311] Aspect 8. A composition comprising two to five serotypes of Coxsackievirus B (CVB), wherein the CVB is in the form of inactivated viral particles (IVPs), CVB virus-like particles (VLPs), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition induces a virus neutralizing antibody titer (VNT) of 1 / 8 to 1 / 64,000 when administered to an individual, as determined by a VNT assay, wherein the composition does not include CVB6.

[0312] Aspect 9. The composition according to aspect 8, wherein the composition comprises two to five serotypes of CVB, wherein the CVB is in the form of inactivated viral particles (IVP), wherein the composition comprises:

[0313] A) Two or more of the following:

[0314] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0315] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0316] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0317] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0318] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0319] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0320] The volume is 100 μL; or

[0321] B) Two or more of the following:

[0322] a) CVB1, the amount of which ranges from 1.0x10 8 IVP to 2.5x10 8 IVPs;

[0323] b) CVB2, the amount of which is from 5.0x10 7 IVP to 1.5x10 8 IVPs;

[0324] c) CVB3, the amount of which is from 5.0x10 8 IVP to 1.5x10 9 IVPs;

[0325] d) CVB4, the amount of which is from 1.0x10 8 IVP to 2.5x10 8 IVPs; and

[0326] e) CVB5, the amount of which is from 2.0x10 8 IVP to 4.0x10 8 an IVP; or

[0327] C) Two or more of the following:

[0328] a) CVB1 protein in an amount ranging from 1 μg to 50 μg;

[0329] b) CVB2 protein in an amount ranging from 1 μg to 50 μg;

[0330] c) CVB3 protein in an amount ranging from 1 μg to 50 μg;

[0331] d) CVB4 protein in an amount ranging from 1 μg to 50 μg; and

[0332] e) CVB5 protein in an amount of from 1 μg to 50 μg,

[0333] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0334] The volume is 500 μL.

[0335] Aspect 10. The composition according to aspect 9, wherein the composition comprises:

[0336] a) CVB1, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs;

[0337] b) CVB2, the amount of which is from 1.0x10 7 IVP to 3.0x10 7 IVPs;

[0338] c) CVB3, the amount of which is from 1.0x10 8 IVP to 3.0x10 8 IVPs;

[0339] d) CVB4, the amount of which is from 2.0x10 7 IVP to 5.0x10 7 IVPs; and

[0340] e) CVB5, the amount of which is from 4.0x10 7 IVP to 8.0x10 7 IVPs,

[0341] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

[0342] Aspect 11. The composition according to aspect 10, wherein the composition comprises:

[0343] a) CVB1, the amount of which is from 3.0x10 7 IVP to 4.0x10 7IVPs;

[0344] b) CVB2, the amount of which is from 1.0x10 7 IVP to 2.0x10 7 IVPs;

[0345] c) CVB3, the amount of which is from 1.0x10 8 IVP to 2.0x10 8 IVPs;

[0346] d) CVB4, the amount of which is from 3.0x10 7 IVP to 4.0x10 7 IVPs; and

[0347] e) CVB5, the amount of which is from 6.0x10 7 IVP to 6.0x10 7 IVPs,

[0348] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

[0349] Aspect 12. The composition according to aspect 9, wherein the composition comprises:

[0350] a) CVB1, the amount is 3.3x10 7 IVPs;

[0351] b) CVB2, the amount of which is 1.1x10 7 IVPs;

[0352] c) CVB3, the amount of which is 1.5x10 8 IVPs;

[0353] d) CVB4, the amount is 3.2x10 7 IVPs; and

[0354] e) CVB5, the amount of which is 6.3x10 7 IVPs,

[0355] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0356] The volume is 100 μl.

[0357] Aspect 13. The composition according to aspect 9, wherein the composition comprises:

[0358] a) CVB1, the amount is 1.6x10 8IVPs;

[0359] b) CVB2, the amount of which is 5.5x10 7 IVPs;

[0360] c) CVB3, the amount of which is 7.5x10 8 IVPs;

[0361] d) CVB4, the amount is 1.6x10 8 IVPs; and

[0362] e) CVB5, the amount of which is 3.1x10 8 IVPs,

[0363] or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides,

[0364] The volume is 500 μL.

[0365] Aspect 14. The composition according to aspect 9, wherein the composition comprises:

[0366] a) CVB1 protein, the amount of which was 2.8 μg;

[0367] b) CVB2 protein, the amount of which was 1.7 μg;

[0368] c) CVB3 protein, the amount of which was 2.7 μg;

[0369] d) CVB4 protein in an amount of 1.2 μg; and

[0370] e) CVB5 protein, the amount of which was 2.3 μg,

[0371] The volume is 100 μl.

[0372] Aspect 15. The composition according to aspect 9, wherein the composition comprises:

[0373] a) CVB1 protein, the amount of which was 14 μg;

[0374] b) CVB2 protein, the amount of which was 8.5 μg;

[0375] c) CVB3 protein, the amount of which was 13.5 μg;

[0376] d) CVB4 protein, in an amount of 6.0 μg; and

[0377] e) CVB5 protein, the amount of which was 11.5 μg,

[0378] The volume is 500 μl.

[0379] Aspect 16. The composition according to any one of aspects 1-5 and 8-13, wherein the IVP is formalin inactivated.

[0380] Aspect 17. The composition according to any one of aspects 1-16, wherein the composition comprises an adjuvant.

[0381] Aspect 18. The composition according to any one of aspects 1-17, comprising saline.

[0382] Aspect 19. A method of inducing an immune response against Coxsackievirus B (CVB) in an individual, the method comprising administering to the individual the composition according to any one of aspects 1-18.

[0383] Aspect 20. The method according to aspect 19, wherein the composition is administered intramuscularly.

[0384] Aspect 21. The method according to aspect 19, wherein the composition is administered subcutaneously.

[0385] Aspect 22. A method of reducing the likelihood that an individual will develop an acute coxsackievirus B (CVB) infection or a CVB infection-related disease, the method comprising administering to the individual a composition according to any one of aspects 1-18.

[0386] Aspect 23. The method according to any one of aspects 19-22, wherein the individual is a neonate.

[0387] Aspect 24. The method according to any one of aspects 19-22, wherein the individual is a pregnant woman.

[0388] Aspect 25. The method according to any one of aspects 19-22, wherein the individual has an increased risk of developing type 1 diabetes.

[0389] Aspect 26. The method according to any one of aspects 19-22, wherein the subject has an increased risk of developing celiac disease.

[0390] Aspect 27. The method according to any one of aspects 19 to 22, wherein the individual is a carrier of an HLADR3 and / or HLADR4 allele.

[0391] Aspect 28. The method according to any one of aspects 19 to 22, wherein prior to said administering, said individual is seropositive for a viral neutralization titer against one or more of CVB1, CVB2, CVB3, CVB4 and CVB5.

[0392] Aspect 29. The method according to any one of aspects 19 to 22, wherein prior to said administering, said individual is seronegative for viral neutralization titers against one or more of CVB1, CVB2, CVB3, CVB4 and CVB5. Example

[0393] The following examples are presented to provide one of ordinary skill in the art with a complete disclosure and description of how to make and use the invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. Standard abbreviations may be used, such as bp, base pairs; kb, kilobase; pl, picoliter; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acids; kb, kilobase; bp, base pairs; nt, nucleotides; im, intramuscular; ip, intraperitoneal; sc, subcutaneous; and the like. Embodiment 1: Induction of VNT in human subjects

[0394] The composition comprising serotypes 1-5 of CVB is administered to normal, healthy human volunteers. Two groups are randomly assigned in a 3 to 1 manner to receive 100 μL or 500 μL of the composition or a matching placebo. Subjects receive 3 doses at monthly intervals. In the follow-up after all subjects complete 3 doses and 1 month after the last dose, VNT analysis is performed. The composition is a formalin-inactivated vaccine comprising CVB serotypes 1 to 5 in the form of inactivated viral particles (IVP). IVP is equivalent to RNA copy number.

[0395] A 100 μL ("low dose") composition included the following amounts of CVB1-CVB5:

[0396] a) CVB1: 3.3x10 7 IVPs;

[0397] b) CVB2: 1.1x10 7 IVPs;

[0398] c)CVB3 1.5x10 8 IVPs;

[0399] d) CVB4: 3.2x10 7 IVPs; and

[0400] e) CVB5: 6.3x10 7IVPs.

[0401] The 500 μL ("high dose") composition included the following amounts of CVB1-CVB5:

[0402] a) CVB1: 1.6x10 8 IVPs;

[0403] b) CVB2: 5.5x10 7 IVPs;

[0404] c) CVB3: 7.5x10 8 IVPs;

[0405] d) CVB4: 1.6x10 8 IVPs; and

[0406] e) CVB5: 3.1x10 8 IVPs.

[0407] No treatment-emergent serious adverse events (SAEs) were observed in any subject. No treatment-emergent adverse events of special interest (AESIs) were observed in any subject.

[0408] A dose-dependent generation of high virus neutralization titers (VNT) was observed. Blue: low dose; red: high dose. The data are shown in Figure 2. As shown in Figure 2, titers ranging from 1 / 2,000-1 / 4,000 were observed. Preexisting anti-CVB virus titers in approximately 40% of the subjects explained the baseline VNT in all groups. The peak VNT titers for antibodies to each serotype are shown in Figure 3 middle. VNT in seropositive and seronegative individuals

[0409] VNTs to each of CVB1 to CVB5 were tested both before and after vaccination. Data are depicted in Figure 4-Figure 13 middle. Figure 4-Figure 13 A curve of mean (+ / - standard deviation) of anti-CVB virus neutralizing antibody titers by visit, baseline seroconversion, and serotype is provided.

[0410] Figure 4-Figure 13 VNT against CVB1 in sera of vaccinated human subjects is depicted ( Figure 4 and Figure 5 ), VNT for CVB2( Figure 6 and Figure 7 ), VNT for CVB3( Figure 8 and Fig. 9 ), VNT for CVB4( Fig.10 and Fig.11), and VNT targeting CBV5 ( Fig.12 and Fig.13 The subject was seropositive for VNT against the indicated CVB serotype prior to vaccination ( Figure 4 , Figure 6 , Figure 8 , Fig.10 and Fig.12 ) or were seronegative before vaccination ( Figure 5 , Figure 7 , Fig. 9 , Fig.11 and Fig.13 ). Response rate

[0411] The response rate of vaccinated human subjects was evaluated. Responders were defined as: a) subjects who were seronegative at baseline and seroconverted (i.e., VNT ≥ 1 / 4) at any time point after vaccination; or b) subjects who were positive for antibodies at baseline (i.e., subjects with pre-existing antibodies) and had a 4-fold or greater increase in VNT at any time point after vaccination.

[0412] The data are shown in Table 1 below. Table 1 Placebo Low dose High dose CVB1 12.5 100 100 CVB2 0 100 100 CVB3 0 75 100 CVB4 0 100 100 CVB5 0 91.7 100 All CVB1-CVB5 0 66.7 100 Results at 6-month time point (week 32)

[0413] The levels of VNT were measured at different time points (weeks 4, 8, 12 and 32) after administration of the first dose of the CVB vaccine composition. The results are shown in Fig.14 , Fig.15 and Fig.17 middle.

[0414] like Fig.14 As shown, among baseline seronegative subjects, at Week 32 (i.e., 24 weeks after the last dose at Week 12), 90% of subjects in the high-dose group had titers equal to or greater than 1 / 8 against all 5 serotypes (VNT). Fig.14 As shown, at week 32, 75% of subjects in the low-dose group had titers equal to or greater than 1 / 8 against all 5 serotypes.

[0415] like Fig.15 As shown, a commercial ELISA assay (DRG International) showed a dose- and time-dependent persistent enterovirus-specific IgG response.

[0416] Fig.17CVB neutralizing antibody titers are depicted for all subjects (baseline seropositive and baseline seronegative). The titers are expressed on a logarithmic (log2) scale. In addition to the time response and dose response, the durability of the response at week 32 was clear for all serotypes in the vaccine.

[0417] The data show the persistence of the VNT reaction for all CVB strains (CVB1-5) in the vaccine. At the last time point (week 32) of 6 months after the last administration, the percentage of subjects who maintained high titer VNT for 4 serotypes in the high-dose PRV-01 group was 100%, and the percentage of subjects who maintained high titer VNT for all 5 serotypes included in the vaccine was 90%. These data confirm the persistence of the reaction. High titer is defined as >=1 / 8, and this level is considered to have clinical protective effects in the only other enterovirus vaccine (inactivated polio vaccine) available on the market. Evidence of VNT cross-reactivity to CVB6 (less common CVB serotype, not included in the CVB vaccine composition) was observed. In addition to VNT, commercial ELISA assays are shown in dose- and time-dependent persistent IgG responses after the initial robust IgM response transition, as well as partial IgA responses (indicating a certain degree of mucosal immunity). Example 2

[0418] The composition comprising serotypes 1-5 of CVB was administered to normal, healthy human volunteers. Two groups were randomly assigned in a 3 to 1 manner to receive 100 μL or 500 μL of the composition or a matching placebo. Subjects received 3 doses at monthly intervals. VNT was analyzed after all subjects completed 3 doses. The final analysis was performed 6 months after the last dose of the vaccine (week 32 of the study). The composition is a formalin-inactivated vaccine comprising CVB serotypes 1 to 5 in the form of IVP.

[0419] The results showed that high titers of VNTs against all five serotypes were induced in a dose-dependent manner. This response was durable: 6 months after the last dose of the vaccine, high levels of protective antibodies were obtained in 100% of the subjects for most serotypes included in the vaccine and in no less than 90% of the subjects for all serotypes included in the vaccine. Data are shown in Fig.17 and Fig.18 middle.

[0420] like Fig.16 As shown, IgG anti-CVB antibodies were generated in a dose-dependent manner. The data show the durability of the IgG response at week 32. Similar data were obtained for IgM.

[0421] Fig.18Dose-dependent production of high titer VNTs against all serotypes (CVB1, CVB2, CVB3, CVB4, and CVB5) was shown. Among baseline seronegative subjects, at Week 32, 100% of subjects had neutralizing antibody titers of 1 / 8 or higher against at least 4 serotypes, and no less than 90% of subjects had neutralizing antibody titers of 1 / 8 or higher against all 5 serotypes included in the vaccine. Example 3

[0422] Neutralizing antibodies were measured against CVB6 and Coxsackievirus A9 (CAV9) using a plaque neutralizing antibody assay. Neutralizing antibodies were analyzed from baseline serum samples collected at the time of the first vaccination and from samples collected one month after the third vaccination.

[0423] A total of 64 serum samples were analyzed for neutralizing CVB antibodies, including 32 V2 samples and 32 V11 samples. Antibody levels at these two time points indicate whether the PRV-101 vaccine induces cross-reactive antibodies in subjects who were initially CVB6 / CAV9 seronegative, or increases antibody titers in subjects who were initially seropositive. The results suggest that the PRV-101 vaccine induces a certain degree of cross-reactive neutralizing antibodies against CVB6. No cross-reactivity was observed against CAV9.

[0424] A total of 8 trial participants experienced seroconversion or a 4-fold or greater increase in neutralizing antibodies to CVB6. All 8 responders were in the vaccinated trial group and none were in the placebo group. None of the trial participants reacted to CVA9. The data suggest that, given the similarities between CVB viruses, a vaccine containing some but not all six known CVB serotypes may improve protection against all six CVB serotypes. Thus, the immunogenic composition may be a vaccine based on 1 to 5 CVB strains, but with improved protection against one or more CVB strains that are not in the vaccine.

[0425] Although the present invention has been described with reference to specific embodiments of the present invention, it will be appreciated by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the present invention. In addition, many modifications may be made to adapt to specific situations, materials, material compositions, processes, process steps or steps to achieve the purpose, spirit and scope of the present invention. All such modifications are intended to be within the scope of the appended claims.

Claims

1. A composition comprising two to five serotypes of Coxsackievirus B (CVB), wherein the CVB is in the form of inactivated viral particles (IVPs), virus-like particles (VLPs), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition comprises: A) two or more of the following: a) CVB1, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; b) CVB2, in an amount ranging from 1.0 x 10 7 IVP to 3.0x 10 7 IVPs; c) CVB3, in an amount ranging from 1.0 x 10 8 IVP to 3.0x 10 8 IVPs; d) CVB4, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; and e) CVB5, in an amount ranging from 4.0 x 10 7 IVP to 8.0x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 100 μL; or B) Two or more of the following: a) CVB1, in an amount ranging from 1.0 x 10 8 IVP to 2.5x 10 8 IVPs; b) CVB2, in an amount ranging from 5.0 x 10 7 IVP to 1.5x 10 8 IVPs; c) CVB3, in an amount ranging from 5.0 x 10 8 IVP to 1.5x 10 9 IVPs; d) CVB4, in an amount ranging from 1.0 x 10 8 IVP to 2.5x 10 8 IVPs; and e) CVB5, in an amount ranging from 2.0 x 10 8 IVP to 4.0x 10 8 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 500 μL; or C) Two or more of the following: a) CVB1 protein in an amount ranging from 1 μg to 50 μg; b) CVB2 protein in an amount ranging from 1 μg to 50 μg; c) CVB3 protein in an amount ranging from 1 μg to 50 μg; d) CVB4 protein in an amount ranging from 1 μg to 50 μg; and e) CVB5 protein in an amount of from 1 μg to 50 μg, wherein the composition does not include CVB6.

2. The composition according to claim 1, wherein the composition comprises: a) CVB1, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; b) CVB2, in an amount ranging from 1.0 x 10 7 IVP to 3.0x 10 7 IVPs; c) CVB3, in an amount ranging from 1.0 x 10 8 IVP to 3.0x 10 8 IVPs; d) CVB4, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; and e) CVB5, in an amount ranging from 4.0 x 10 7 IVP to 8.0x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 100 μl.

3. The composition according to claim 2, wherein the composition comprises: a) CVB1, in an amount ranging from 3.0 x 10 7 IVP to 4.0x 10 7 IVPs; b) CVB2, in an amount ranging from 1.0 x 10 7 IVP to 2.0x 10 7 IVPs; c) CVB3, in an amount ranging from 1.0 x 10 8 IVP to 2.0x 10 8 IVPs; d) CVB4, in an amount ranging from 3.0 x 10 7 IVP to 4.0x 10 7 IVPs; and e) CVB5, in an amount ranging from 6.0 x 10 7 IVP to 6.0x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

4. The composition according to claim 1, wherein the composition comprises: a) CVB1, the amount of which is 3.3 x 10 7 IVPs; b) CVB2, in an amount of 1.1 x 10 7 IVPs; c) CVB3, in an amount of 1.5 x 10 8 IVPs; d) CVB4, the amount of which is 3.2 x 10 7 IVPs; and e) CVB5, the amount of which was 6.3 x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 100 μl.

5. The composition according to claim 1, wherein the composition comprises: a) CVB1, the amount of which was 1.6 x 10 8 IVPs; b) CVB2, in an amount of 5.5 x 10 7 IVPs; c) CVB3, in an amount of 7.5 x 10 8 IVPs; d) CVB4, the amount of which was 1.6 x 10 8 IVPs; and e) CVB5, the amount of which was 3.1 x 10 8 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 500 μL.

6. The composition according to claim 1, wherein the composition comprises: a) CVB1 protein, the amount of which was 2.8 μg; b) CVB2 protein, the amount of which was 1.7 μg; c) CVB3 protein, the amount of which was 2.7 μg; d) CVB4 protein in an amount of 1.2 μg; and e) CVB5 protein, the amount of which was 2.3 μg, The volume is 100 μl.

7. The composition according to claim 1, wherein the composition comprises: a) CVB1 protein, the amount of which was 14 μg; b) CVB2 protein, the amount of which was 8.5 μg; c) CVB3 protein, the amount of which was 13.5 μg; d) CVB4 protein, in an amount of 6.0 μg; and e) CVB5 protein, the amount of which was 11.5 μg, The volume is 500 μl.

8. A composition comprising two to five serotypes of Coxsackievirus B (CVB), wherein the CVB is in the form of inactivated viral particles (IVPs), CVB virus-like particles (VLPs), one or more CVB polypeptides, or one or more nucleic acids comprising nucleotide sequences encoding the one or more CVB polypeptides, wherein the composition induces a virus neutralizing antibody titer (VNT) of 1 / 8 to 1 / 64,000 when administered to an individual, as determined by a VNT assay, wherein the composition does not include CVB6.

9. The composition according to claim 8, wherein the composition comprises two to five serotypes of CVB, wherein the CVB is in the form of inactivated viral particles (IVP), wherein the composition comprises: A) Two or more of the following: a) CVB1, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; b) CVB2, in an amount ranging from 1.0 x 10 7 IVP to 3.0x 10 7 IVPs; c) CVB3, in an amount ranging from 1.0 x 10 8 IVP to 3.0x 10 8 IVPs; d) CVB4, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; and e) CVB5, in an amount ranging from 4.0 x 10 7 IVP to 8.0x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 100 μL; or B) Two or more of the following: a) CVB1, in an amount ranging from 1.0 x 10 8 IVP to 2.5x 10 8 IVPs; b) CVB2, in an amount ranging from 5.0 x 10 7 IVP to 1.5x 10 8 IVPs; c) CVB3, in an amount ranging from 5.0 x 10 8 IVP to 1.5x 10 9 IVPs; d) CVB4, in an amount ranging from 1.0 x 10 8 IVP to 2.5x 10 8 IVPs; and e) CVB5, in an amount ranging from 2.0 x 10 8 IVP to 4.0x 10 8 an IVP; or C) Two or more of the following: a) CVB1 protein in an amount ranging from 1 μg to 50 μg; b) CVB2 protein in an amount ranging from 1 μg to 50 μg; c) CVB3 protein in an amount ranging from 1 μg to 50 μg; d) CVB4 protein in an amount ranging from 1 μg to 50 μg; and e) CVB5 protein in an amount of from 1 μg to 50 μg, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 500 μL.

10. The composition according to claim 9, wherein the composition comprises: a) CVB1, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; b) CVB2, in an amount ranging from 1.0 x 10 7 IVP to 3.0x 10 7 IVPs; c) CVB3, in an amount ranging from 1.0 x 10 8 IVP to 3.0x 10 8 IVPs; d) CVB4, in an amount ranging from 2.0 x 10 7 IVP to 5.0x 10 7 IVPs; and e) CVB5, in an amount ranging from 4.0 x 10 7 IVP to 8.0x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

11. The composition according to claim 10, wherein the composition comprises: a) CVB1, in an amount ranging from 3.0 x 10 7 IVP to 4.0x 10 7 IVPs; b) CVB2, in an amount ranging from 1.0 x 10 7 IVP to 2.0x 10 7 IVPs; c) CVB3, in an amount ranging from 1.0 x 10 8 IVP to 2.0x 10 8 IVPs; d) CVB4, in an amount ranging from 3.0 x 10 7 IVP to 4.0x 10 7 IVPs; and e) CVB5, in an amount ranging from 6.0 x 10 7 IVP to 6.0x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding the one or more CVB polypeptides.

12. The composition according to claim 9, wherein the composition comprises: a) CVB1, the amount of which is 3.3 x 10 7 IVPs; b) CVB2, in an amount of 1.1 x 10 7 IVPs; c) CVB3, in an amount of 1.5 x 10 8 IVPs; d) CVB4, the amount of which is 3.2 x 10 7 IVPs; and e) CVB5, the amount of which was 6.3 x 10 7 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 100 μl.

13. The composition according to claim 9, wherein the composition comprises: a) CVB1, the amount of which was 1.6 x 10 8 IVPs; b) CVB2, in an amount of 5.5 x 10 7 IVPs; c) CVB3, in an amount of 7.5 x 10 8 IVPs; d) CVB4, the amount of which was 1.6 x 10 8 IVPs; and e) CVB5, the amount of which was 3.1 x 10 8 IVPs, or an equivalent amount of VLPs, one or more CVB polypeptides, or one or more nucleic acids containing nucleotide sequences encoding said one or more CVB polypeptides, The volume is 500 μL.

14. The composition according to claim 9, wherein the composition comprises: a) CVB1 protein, the amount of which was 2.8 μg; b) CVB2 protein, the amount of which was 1.7 μg; c) CVB3 protein, the amount of which was 2.7 μg; d) CVB4 protein in an amount of 1.2 μg; and e) CVB5 protein, the amount of which was 2.3 μg, The volume is 100 μl.

15. The composition according to claim 9, wherein the composition comprises: a) CVB1 protein, the amount of which was 14 μg; b) CVB2 protein, the amount of which was 8.5 μg; c) CVB3 protein, the amount of which was 13.5 μg; d) CVB4 protein, in an amount of 6.0 μg; and e) CVB5 protein, the amount of which was 11.5 μg, The volume is 500 μl.

16. The composition of any one of claims 1-5 and 8-13, wherein the IVP is formalin inactivated.

17. The composition of any one of claims 1-16, wherein the composition comprises an adjuvant.

18. The composition of any one of claims 1-17, comprising saline.

19. A method of inducing an immune response against Coxsackievirus B (CVB) in an individual, the method comprising administering to the individual a composition according to any one of claims 1-18.

20. The method of claim 19, wherein the composition is administered intramuscularly.

21. The method of claim 19, wherein the composition is administered subcutaneously.

22. A method of reducing the likelihood that an individual will develop an acute coxsackievirus B (CVB) infection or a CVB infection-related disease, the method comprising administering to the individual a composition according to any one of claims 1-18.

23. The method of any one of claims 19-22, wherein the individual is a neonate.

24. The method of any one of claims 19-22, wherein the individual is a pregnant woman.

25. The method of any one of claims 19-22, wherein the individual has an increased risk of developing type 1 diabetes.

26. The method of any one of claims 19-22, wherein the individual is at increased risk for developing celiac disease.

27. The method of any one of claims 19-22, wherein the individual is a carrier of an HLA DR3 and / or HLA DR4 allele.

28. The method of any one of claims 19-22, wherein prior to said administering, said individual is seropositive for viral neutralization titers against one or more of CVB1, CVB2, CVB3, CVB4, and CVB5.

29. The method of any one of claims 19-22, wherein prior to said administering, said individual is seronegative for viral neutralization titers against one or more of CVB1, CVB2, CVB3, CVB4, and CVB5.